Skip to content
Stivarga(regorafenib)
Stivarga (regorafenib) is a small molecule pharmaceutical. Regorafenib was first approved as Stivarga on 2012-09-27. It is used to treat colorectal neoplasms, gastrointestinal stromal tumors, and hepatocellular carcinoma in the USA. It has been approved in Europe to treat colorectal neoplasms. The pharmaceutical is active against serine/threonine-protein kinase B-raf. In addition, it is known to target vascular endothelial growth factor receptor 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Stivarga
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Regorafenib
Tradename
Company
Number
Date
Products
STIVARGABayerN-203085 RX2012-09-27
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
stivargaNew Drug Application2020-12-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasms—D015179—
gastrointestinal stromal tumorsEFO_0000505D046152C49.A
hepatocellular carcinoma—D006528C22.0
Agency Specific
FDA
EMA
Expiration
Code
REGORAFENIB, STIVARGA, BAYER HLTHCARE
2024-04-27ODE-139
Patent Expiration
Patent
Expires
Flag
FDA Information
Regorafenib, Stivarga, Bayer Hlthcare
99572322032-07-09DP
94581072031-04-08DP
86375532031-02-16DS, DP
86801242030-06-02U-1506
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX05: Regorafenib
HCPCS
No data
Clinical
Clinical Trials
237 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517919521631590
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A2721314
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.03132—521
Hepatocellular carcinomaD006528C22.0131—27
GlioblastomaD005909EFO_0000515—31—14
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801811——227
SarcomaD01250917———7
AdenocarcinomaD00023036———7
Pancreatic neoplasmsD010190EFO_0003860C2515———6
Rectal neoplasmsD01200424———6
OsteosarcomaD01251615——16
Ovarian neoplasmsD010051EFO_0003893C56—5———5
Renal cell carcinomaD00229214———5
Colonic neoplasmsD003110C1822———4
Non-small-cell lung carcinomaD00228913———3
Show 42 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.02————2
PharmacokineticsD0105992————2
Myelodysplastic syndromesD009190D461————1
Hematologic neoplasmsD0193371————1
Prostatic neoplasmsD011471C611————1
Primary myelofibrosisD055728D47.41————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Myelomonocytic leukemia chronicD015477C93.11————1
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameREGORAFENIB
INNregorafenib
Description
Regorafenib is a pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It is an aromatic ether, a pyridinecarboxamide, a member of monochlorobenzenes, a member of (trifluoromethyl)benzenes, a member of monofluorobenzenes and a member of phenylureas.
Classification
Small molecule
Drug classrapidly accelerated fibrosarcoma (RAF) kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)c(F)c2)ccn1
Identifiers
PDB—
CAS-ID755037-03-7
RxCUI1312397
ChEMBL IDCHEMBL1946170
ChEBI ID68647
PubChem CID11167602
DrugBankDB08896
UNII ID24T2A1DOYB (ChemIDplus, GSRS)
Target
Agency Approved
BRAF
BRAF
Organism
Homo sapiens
Gene name
BRAF
Gene synonyms
BRAF1, RAFB1
NCBI Gene ID
673
Protein name
serine/threonine-protein kinase B-raf
Protein synonyms
94 kDa B-raf protein, B-Raf proto-oncogene serine/threonine-protein kinase (p94), B-Raf serine/threonine-protein, murine sarcoma viral (v-raf) oncogene homolog B1, p94, Proto-oncogene B-Raf, v-raf murine sarcoma viral oncogene homolog B, v-Raf murine sarcoma viral oncogene homolog B1
Uniprot ID
Q9Y6T3
Mouse ortholog
Braf (109880)
serine/threonine-protein kinase B-raf (P28028)
Alternate
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
3791
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Q14178
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 9,315 documents
View more details
Safety
Black-box Warning
Black-box warning for: Stivarga
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
4,158 adverse events reported
View more details